Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer

Documenti analoghi

• Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer
  di: Emmanuel Chigutsa, et al.
  Pubblicazione: (2026)
• Partial Residual Plots as an Integrated Model Diagnostic Tool in Model‐Based Meta‐Analysis
  di: John Maringwa, et al.
  Pubblicazione: (2024)
• Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
  di: Jatinder Kaur Mukker, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children
  di: Sylvie Retout, et al.
  Pubblicazione: (2026)
• Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
  di: Sumit Bhatnagar, et al.
  Pubblicazione: (2024)